XML 58 R44.htm IDEA: XBRL DOCUMENT
v3.21.2

RESEARCH AND LICENSE AGREEMENTS (Details Narrative) - USD ($) |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |
--- | --- | --- | --- | --- | ---
Jun. 30, 2020 | Jun. 30, 2020 | Nov. 30, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | Jun. 30, 2018 | Jun. 30, 2021 | Mar. 30, 2021 | Jun. 30, 2020 | Mar. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  | $ 4,508,466 |  | $ 597,345 |  | $ 8,007,840 | $ 835,403 |
Product sales |  |  |  |  |  |  |  |  |  | 1,117,935 |  | 904,067 |  | 3,017,430 | 2,360,823 |
Collaborative Research Revenue [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 45,000 |
License Revenue [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |  |  |  | 478,654 |  |
University Of Louisville Research Foundation [Member] | Minimum [Member] | Royalties And Non Royalty Sublicensee Income [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shortfall payments | $ 5,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
University Of Louisville Research Foundation [Member] | Maximum [Member] | Royalties And Non Royalty Sublicensee Income [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shortfall payments |  | $ 50,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Prediction Biosciences S A S [Member] | Collaborative Research Revenue [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  | 45,000 | 0 |
Sekisui Diagnostics L L C [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  | 701,000 | $ 1,700,000 | 420,000 | $ 1,400,000 |  |  |
Yi Xin Zhen Duan Jishu Ltd [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |  |  |  | 38,000 |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | 420,000 |  |  |  | 420,000 |  | $ 250,000
Yi Xin Zhen Duan Jishu Ltd [Member] | License Revenue [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product sales |  |  |  |  |  |  |  |  |  |  |  |  |  | 479,000 |  |
S T A Pharmaceutical Co Ltd [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  | 1,900,000 |  | 0 |  | 3,100,000 | 0 |
Upfront deposit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,100,000
License And Sponsored Research Agreements [Member] | University Of Louisville Research Foundation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment of convertible promissory note |  |  |  | $ 50,000 |  |  |  |  | $ 50,000 |  |  |  |  |  |  |
Reimbursement of research expenses |  |  |  | 805,000 |  |  |  |  | 805,000 |  |  |  |  |  |  |
Reimbursement patent cost |  |  |  | $ 200,000 |  |  |  |  | $ 200,000 |  |  |  |  |  |  |
Agreement term payment, description |  |  |  | In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones. |  |  |  |  | In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones. |  |  |  |  |  |  |
Milestone payment for marketing expenses |  |  |  | $ 500,000 |  |  |  |  | $ 500,000 |  |  |  |  |  |  |
Licensed product sales, revenue |  |  |  | 500,000,000 |  |  |  |  | 500,000,000 |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  | 99,000 |  | 139,000 |  | 206,000 | 247,000 |
License costs |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  | 40,000 | 0 |
License And Sponsored Research Agreements [Member] | University Of Louisville Research Foundation [Member] | Licensed Product Sales [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Regulatory marketing approval, expenses |  |  |  |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |
License And Sponsored Research Agreements [Member] | University Of Louisville Research Foundation [Member] | Phase One Clinical Trial [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  | 100,000 |  | 50,000 |  |  | 100,000 |  |  |  |  |  |  |
License And Sponsored Research Agreements [Member] | University Of Louisville Research Foundation [Member] | Phase Two Clinical Trial [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  | 200,000 |  | 100,000 |  |  | 200,000 |  |  |  |  |  |  |
License And Sponsored Research Agreements [Member] | University Of Louisville Research Foundation [Member] | Phase Three Clinical Trial [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  | 350,000 |  | 150,000 |  |  | 350,000 |  |  |  |  |  |  |
License And Sponsored Research Agreements [Member] | University Of Louisville Research Foundation [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  | 100,000 |  |  |  |  | 100,000 |  |  |  |  |  |  |
Shortfall payments |  |  |  | 10,000 |  |  |  |  | 10,000 |  |  |  |  |  |  |
License And Sponsored Research Agreements [Member] | University Of Louisville Research Foundation [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  | 5,000,000 |  |  |  |  | 5,000,000 |  |  |  |  |  |  |
Shortfall payments |  |  |  | $ 50,000 |  |  |  |  | $ 50,000 |  |  |  |  |  |  |
Sponsored Research Agreement And License [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  | 89,000 |  | 2,000 |  | 152,000 | 2,000 |
Minimum annual royalties |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  | 0 | 10,000 |
License costs |  |  |  |  |  |  |  |  |  | 17,000 |  | 0 |  | 53,000 | 0 |
Sponsored Research Agreement And License [Member] | University Of Louisville Research Foundation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reimbursement of research expenses |  |  |  |  |  | 693,000 | $ 1,400,000 |  |  |  |  |  |  |  |  |
Reimbursement patent cost |  |  |  |  |  | $ 112,000 |  |  |  |  |  |  |  |  |  |
Agreement term payment, description |  |  |  |  |  | In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones. |  |  |  |  |  |  |  |  |  |
Licensed product sales, revenue |  |  |  |  |  | $ 500,000,000 |  |  |  |  |  |  |  |  |  |
Regulatory marketing approval, expenses |  |  |  |  |  | 300,000 |  |  |  |  |  |  |  |  |  |
Sponsored Research Agreement And License [Member] | University Of Louisville Research Foundation [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  | 50,000 |  |  |  |  |  |  |  |  |  |
Sponsored Research Agreement And License [Member] | University Of Louisville Research Foundation [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  | 5,000,000 |  |  |  |  |  |  |  |  |  |
License Agreement [Member] | University Of Louisville Research Foundation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License costs |  |  |  |  |  |  |  |  |  | 16,000 |  |  |  | 16,000 | 0 |
Upfront license fee | $ 24,000 | $ 24,000 |  |  | $ 24,000 |  |  |  |  |  |  | 24,000 |  |  | 24,000 |
ULRF license agreement description |  |  |  |  | In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of QN-165 as a treatment for COVID-19, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patents, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones. |  |  |  |  |  |  |  |  |  |  |
Sponsored research expense |  |  |  |  |  |  |  |  |  | 25,000 |  | 0 |  | 94,000 | 0 |
License Agreement [Member] | University Of Louisville Research Foundation [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fee |  |  |  |  |  | 20,000 |  |  |  |  |  |  |  |  |  |
License Agreement [Member] | University Of Louisville Research Foundation [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  | $ 430,000 |  | $ 250,000 |  |  |  |  |  |  |  |  |  |  |
Upfront license fee |  |  |  |  |  | $ 100,000 |  |  |  |  |  |  |  |  |  |
License Agreement [Member] | Advanced Cancer Therapeutics L L C [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licensed product sales, revenue |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |
License costs |  |  |  |  |  |  |  |  |  | 0 |  | $ 0 |  | 2,000 | $ 0 |
Agreement description |  |  |  |  |  |  |  | the Company entered into a license agreement with Advanced Cancer Therapeutics, LLC (“ACT”), granting the Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate. In return, ACT received a $25,000 convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company’s common stock. In addition, the Company agreed to pay ACT (i) royalties, on net sales associated with the commercialization of QN-165, of 2% (only if patent-covered and only on net sales above a cumulative $3,000,000) or 1% (if not patent-covered, but only on net sales above a cumulative $3,000,000) |  |  |  |  |  |  |  |
Proceeds from convertible promissory note |  |  |  |  |  |  |  | $ 25,000 |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  |  | 100,000 |  |  |  |  |  |  |  |
Cumulative amount |  |  |  |  |  |  |  | 2,000,000 |  |  |  |  |  |  |  |
License Agreement [Member] | Advanced Cancer Therapeutics L L C [Member] | C E Mark [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  |  | 100,000 |  |  |  |  |  |  |  |
Cumulative amount |  |  |  |  |  |  |  | $ 500,000 |  |  |  |  |  |  |  |
Technology Transfer Agreement [Member] | Yi Xin Zhen Duan Jishu Ltd [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Entity Listings [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | $ 153,000 |  |  |  | $ 153,000 |  |

X
- Definition Agreement description. + References No definition available. + Details
Name: | QLGN_AgreementDescription
Namespace Prefix: | QLGN_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Agreement term payment, description. + References No definition available. + Details
Name: | QLGN_AgreementTermPaymentDescription
Namespace Prefix: | QLGN_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cumulative amount. + References No definition available. + Details
Name: | QLGN_CumulativeAmount
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License costs. + References No definition available. + Details
Name: | QLGN_LicenseCost
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone method revenue recognized. + References No definition available. + Details
Name: | QLGN_MilestoneMethodRevenueRecognized
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment. + References No definition available. + Details
Name: | QLGN_MilestonePayment
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payment for marketing expenses. + References No definition available. + Details
Name: | QLGN_MilestonePaymentForMarketingExpenses
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Regulatory marketing approval, expenses. + References No definition available. + Details
Name: | QLGN_RegulatoryMarketingApprovalExpenses
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reimbursement of research expenses. + References No definition available. + Details
Name: | QLGN_ReimbursementOfResearchExpenses
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reimbursement patent cost. + References No definition available. + Details
Name: | QLGN_ReimbursementPatentCost
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Shortfall payments. + References No definition available. + Details
Name: | QLGN_ShortfallPayments
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition ULRF license agreement description. + References No definition available. + Details
Name: | QLGN_UlrfLicenseAgreementDescription
Namespace Prefix: | QLGN_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront license fee. + References No definition available. + Details
Name: | QLGN_UpfrontLicenseFee
Namespace Prefix: | QLGN_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | dei_EntityListingsLineItems
Namespace Prefix: | dei_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(5)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8,17) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DepositAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of other research and development expense. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromConvertibleDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585 + Details
Name: | us-gaap_RepaymentsOfConvertibleDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=QLGN_CollaborativeResearchRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=QLGN_LicenseRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=QLGN_UniversityOfLouisvilleResearchFoundationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=QLGN_RoyaltiesAndNonRoyaltySublicenseeIncomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=QLGN_PredictionBiosciencesSASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=QLGN_SekisuiDiagnosticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=QLGN_YiXinZhenDuanJishuLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=QLGN_STAPharmaceuticalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=QLGN_LicensedProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=QLGN_PhaseOneClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=QLGN_PhaseTwoClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=QLGN_PhaseThreeClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=QLGN_AdvancedCancerTherapeuticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=QLGN_CEMarkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=QLGN_TechnologyTransferAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |